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A b s t r a c t
AIM: Prostaglandin G/H synthase 2 (PTGS2 or COX2) is
one of the key factors in the cellular response to inflammation.
PTGS2 is expressed in the affected intestinal segments
of patients with inflammatory bowel diseases (IBD). In
IBD patients, non-steroidal anti-inflammatory drugs, which
have been shown to reduce both the production and activity
of PTGS2, may activate IBD and aggravate the symptoms.
We aimed at examining genetic variants of PTGS2 that
may be risk factors for IBD.
METHODS: We  genotyped 291 individuals diagnosed with
IBD and 367 controls from the Dutch population for the
five most frequent polymorphisms of the PTGS2 gene.
Clinical data were collected on all patients. DNA was
extracted via normal laboratory methods. Genotyping was
carried out using multiplex PCR followed by the Invader
Assay and the 5’ exonuclease assay (TaqMan). New
polymorphism screening was performed by pre-screening
with denaturing high-performance liquid chromatography,
followed by fluorescent sequencing.
RESULTS: Allele 5209G was weakly associated with
Crohn’s disease (odds ratio [OR] 1.63, 95% confidence
interval [CI] 1.03-2.57), and allele 8473T with ulcerative
colitis (OR 1.50, 95%CI 1.00-2.27). The haplotype including
both alleles showed a strong association with IBD (OR
13.15, 95%CI 3.17-116.15). This haplotype, while rare
(-0.3%) in the general population, is found more frequently
in  patients (3.5%).
CONCLUSION: Our data suggest that this haplotype of
PTGS2 contributes to the susceptibility of IBD.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Risk factors for inflammatory bowel diseases (IBD) include
several environmental and genetic exposures. Diet, tobacco
smoking, and childhood diseases or poor hygiene have been
identified as risk factors for IBD, with some important
differences between ulcerative colitis (UC) and Crohn’s
disease (CD)[1-3]. Caucasians have been shown to be at higher
risk than non-Caucasians, with North-South gradients seen
in Europe[4,5].
Familial aggregation of  IBD suggests a genetic component
in the susceptibility to IBD. One major locus of susceptibility
to IBD has been mapped by linkage analysis to chromosome
16, at the CARD15/NOD2 gene[6-8], which has a role in
inflammatory responses, through activation of nuclear factor
NF-κB. Two more susceptibility genes have recently been
identified[9,10]. Population-based association studies focused
on polymorphisms of inflammatory genes, such as genes
of  the interleukin-1β pathway. Few showed significant
associations with some degree of contradiction between
studies[11-15].
Key genes involved in the regulation of the inflammatory
processes, such as prostaglandin G/H synthase/cyclooxygenase
(PTGS/COX), are obvious candidates to look for variants
predisposing to IBD. One of  the two PTGS isoforms, PTGS2/
COX2, is expressed in epithelial cells and mononuclear cells
in IBD[4], and it is induced in response to pro-inflammatory
cytokines, including interleukin-1β[16-18]. PTGS2 is the rate-
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limiting enzyme in the production of prostaglandins.
Prostaglandins are thought to be essential in the process of
wound healing in the gastrointestinal tract[19]. The use of
non-steroidal anti-inflammatory drugs (NSAIDs), which
inhibit both the transcription and activity of PTGS2, exacerbates
the symptoms in UC[20] and may even activate quiescent
IBD[21]. Thus, the expression of PTGS2 in the inflamed
intestine might be a protective response within the wound-
healing process[22]. Consequently, polymorphisms that change
the amount of prostaglandins produced in inflamed cells
could cause susceptibility to IBD.
To address this hypothesis, we have studied 145 UC patients,
146 CD patients, and 367 controls from the Dutch Caucasian
population, which has a high incidence of IBD[23]. The
present study was to  search for associations between IBD
and common single nucleotide polymorphisms (SNPs) in
the PTGS2 gene.
MATERIALS AND METHODS
Samples
The recruitment of cases took place at the Department of
Gastroenterology of  the VU University Medical Center
(VUmc), a referral center for IBD, between April 1992 and
September 2000. Patients with indeterminate colitis were
excluded from this study. Seventy-five UC patients were
females and seventy males, with a median age of 46 years
(range 19-89 years). The gender repartition of CD patients
was 101 females and 45 males, with a median age of 40
years (range 15-80 years). The control population consisted
of 175 healthy individuals who were students or staff at
the VUmc, with a median age of 51 years (range 24-88
years). All subjects were unrelated Dutch Caucasians.
Genomic DNA was extracted using the DNAzol procedure
(Invitrogen).
In order to ensure that the control group was representative
of the general population, a second control group was also
used, consisting of 192 Dutch subjects (96 males and 96
females). These samples were selected from the European
Prospective Investigation on Cancer (EPIC) cohort[24] to
provide information on the genetic background in the
overall Dutch population. These samples were selected to
provide a similar age distribution and sex ratio as the original
control group. DNA was extracted from buffy coat using
Puregene chemistry (Gentra Systems, Minneapolis, MN,
USA). This population-based sample was indistinguishable
from the VUmc controls from the point of view of frequencies
of  PTGS2 alleles and genotypes (data not shown). We take
this as confirmation that both groups were drawn from the
general Dutch population, at least from the genetic point
of view.
Patient classification
Diagnosis and assessment of maximal extent of IBD were
based on endoscopic, histopathological, and radiological
criteria[25]. Patients with indeterminate colitis were not
included in this study, as they can be categorized as UC or
CD only at a later stage. UC patients were subdivided into
three groups: proctitis, limited to the rectum (12 cases), left-
sided colitis with disease activity up to the splenic flexure (72
cases), and pancolitis (61 cases), extending beyond the splenic
flexure. In addition, the patients with UC were subdivided
into one group with their colon in situ (116 cases), and a
second group in which (procto)colectomy had to be
performed during the course of  disease (29 cases), indicative
of severe or intractable disease (i.e., unresponsive to medical
therapy). No patient was operated on prophylactic indication.
In CD, patients were subdivided according to the Vienna
classification[26]. This classification subdivides patients with
CD according to age at onset (<40 years [125 cases] or
¡Ý40 years [21 cases]), disease behavior (non-stricturing,
non-penetrating [51 cases], stricturing [63 cases], penetrating
[32 cases]) and location of  disease (terminal ileum [50 cases],
colon [32 cases], ileocolonic [62 cases], or upper gastrointestinal
tract [2 cases]). Anatomical classification is defined as the
maximal extent of the disease prior to the first surgical
procedure, while behavior is assessed at any time during the
course of the disease.
SNP selection and genotyping
SNPs were selected from our previously collected data[27]
to include those SNPs with a prevalence of greater than
5% in Caucasians. Among the SNPs we studied, the only
one with a proven functional role is a SNP located in the
promoter of PTGS2, at position 926 of GenBank entry
D28235 (dbSNP rs20417), which has been shown to affect
the expression of PTGS2 mRNA[28].
The order of samples of patients and controls was
randomized in the PCR plates, so that a uniform number
of patients and controls could be analyzed simultaneously
in each run. EPIC samples were genotyped separately.
Three SNPs were genotyped with the Invader Assay[29].
PCR for the Invader assay (Third Wave Technologies,
Madison, WI, USA) was carried out in 25 μL reactions,
using the following concentrations: 20 ng DNA, 20 μmol/L
dNTPs, 1×Taq Platinum buffer, 1.5 mmol/L MgCl2, 1.25 U
Taq Platinum polymerase (Life Technologies, Inc., Gaithersburg,
MD, USA), 0.5 μmol/L of each primer. The primers used
were as follows (nomenclature of SNPs refers to base numbers
in GenBank entry D28235):
PTGS2.401 (rs689465)
401F: AAG GAC TTA GGA CAT AAC TGA ATT TTC
401R: ATG GGT AGT GCT CAG GGA GGA G
PTGS2.3050 (rs5277)
3050F: CGT TGT GAA TAA CAT TCC CTT
3050R: ATT TTT CTT TGA GAA GGC TAA AA
PTGS2.5209 (rs20432)
5209F: ATG ATG TAT GCC ACA ATC TGG CTG
5209R: TTG TCT GGA ACA ACT GCT CAT CAC.
This multiplex reaction was then carried out in a Tetrad
DNA Engine PCR machine (MJ Research, Waltham, MA,
USA), with the following cycling conditions: 96 ¡æ for 5 min,
then 30 cycles of 96 ¡æ for 30 s, 50 ¡æ for 60 s, and 72 ¡æ
for 10 s, with a final extension of 72 ¡æ for 5 min. PCR
volumes were then brought up to 150 μL, and Invader
reactions were carried out as per manufacturer’s instructions.
Plates were read in a fluorometer with excitation and emission
spectra as recommended by Third Wave.
The SNPs PTGS2.926 and PTGS2.8473 were tested using
the TaqMan assay with MGB chemistry (Applied Biosystems,
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Foster City, CA, USA). The assay was carried out in a 10 μL
reaction, with 20 ng DNA, 1×TaqMan master mix (Applied
Biosystems), 0.1 μmol/L of each primer, and 0.2 μmol/L
of each probe. Primer and probe sequences are as follows:
PTGS2.926 (rs20417)
926F: TTA ACT ATT TAC AGG GTA ACT GCT TAG G
926R: CTT CAC CCC CTC CTT GTT TC
926VIC: CCT TTC CCG CCT CT
926FAM: CTT TCC CCC CTC TC
PTGS2.8473 (rs5275)
8473F: ATG CAC TGA TAC CTG TTT TTG TTT G
8473R: GTT TCC AAT GCA TCT TCC ATG A
8473VIC: TGA CAG AAA AAT AAC CAA AA
8473FAM: TGA CAG AAA AAT GAC CAA A
The cycling conditions for these PCR reactions were as
follows: 95 ¡æ for 10 min, then 35 cycles of 95 ¡æ for 15 s,
and 60 ¡æ (58 ¡æ for PTGS2.926) for 60 s. Plates were
then read in the ABI 7900HT sequence detection system.
Data analysis
For genotype data from the Invader assay, raw intensity
counts were corrected with a negative control, and the ratio
between the two signals (one color for each allele) was used
to call each genotype. For the TaqMan assay, groups of
genotypes (homozygote common, heterozygote, and
homozygote rare) were determined manually within the SDS
software (Applied Biosystems). Each SNP was tested in the
control group to ensure that it does not deviate from Hardy-
Weinberg equilibrium. Linkage disequilibrium tests were
performed using macros developed by the authors in
conjunction with the PHASE program[30] to reconstruct
haplotype frequencies. Odds ratios (OR) and 95% confidence
interval (CI) were calculated in Stata 7.0, using logistic
regressions correcting for sex and age in analyzing genotypes
at single SNPs. Simple OR were calculated when data consisted
of frequencies of alleles or haplotypes in the population.
All P values reported are two sided. SNPs were tested for
effects on splicing using the Delila Server (http://www.
lecb.ncifcrf.gov/-toms/delilaserver.html) at the Laboratory
of  Experimental and Computational Biology of  the National
Cancer Institute[31].
New polymorphism screening
Individuals termed “at risk” based on association testing (i.e.,
the 19 cases carrying the haplotype, which includes the two
alleles showing increase in risk at SNPs 5 209 and 8 473)
were screened for novel polymorphisms using denaturing
high-performance liquid chromatography (DHPLC) via the
WAVE system (Transgenomic, Omaha, NE, USA). The areas
studied were the promoter region, exons 6 and 10, and the 3’
UTR. The protocols followed were as published previously[27].
R E S U L T S
Figure 1 shows a graphical representation of the structure
of the PTGS2 gene. The five major SNPs as well as the
polymorphisms discovered as part of this study are depicted.
The allele frequencies of the five major SNPs in the control
group were 11.4% (PTGS2.401), 13.4% (PTGS2.926),
14.6% (PTGS2.3050), 13.5% (PTGS2.5209), and 33.9%
(PTGS2.8473). All SNPs, except PTGS2.3050, were in
Hardy-Weinberg equilibrium in the control group. Table 1
shows the genotype counts of the SNPs studied, among
cases and controls. The SNP at position 5 209 shows an
increase in the carriers of the G allele in cases as compared
to controls, with a weak but significant association was found
only in CD (OR = 1.63, 95%CI 1.03-2.57, P = 0.04). The
SNP at position 8 473 shows an increase in the frequency
of the T/T homozygote genotype in cases as compared to
controls, with an association of borderline significance found
only in UC (OR = 1.50, 95%CI 1.00-2.27, P = 0.05). No
association was seen with the SNPs at position 401, 926, or
3 050, although it should be noted that there is a lack of
homozygous rare genotypes at bp 3 050 in the control group,
which is the reason for its departure from Hardy-Weinberg
equilibrium.
We analyzed differences in genotype counts among the
different clinical variables for CD and UC. No statistically
significant differences between classification levels were
observed (data not shown).
Significant levels of linkage disequilibrium were seen
among the most common SNPs in the PTGS2 gene (data
not shown). Table 2 shows the frequencies of  haplotypes
of the PTGS2 gene in both IBD patients and controls. The
SNP at bp 3 050 was not included in haplotype analysis, as
it was not in Hardy-Weinberg equilibrium in the control
population, and this has been shown to affect the accuracy
of haplotype reconstruction methods[32]. All individuals were
genotyped for the SNP at bp 3 050, eliminating the risk that
its lack of  Hardy-Weinberg equilibrium is caused by bias
due to the genotyping technique missing preferentially one
genotype. Haplotype frequencies were calculated using all
four valid SNPs, and all data are shown. There were no
differences in haplotype frequency between the two groups
of  IBD patients and the controls, except for haplotype AGGT,
which shows an OR of 11.9 (95%CI 2.83-105.76, P<0.00005,
for UC and CD combined). Interestingly, this haplotype
includes the two alleles showing an increase in risk at SNPs
5 209 and 8 473. If we consider the haplotype including
the 5209.G and 8473.T alleles (by lumping haplotypes
Figure 1  Structure of PTGS2. Positions in base pairs as per GenBank sequence
D28235. Exons are shown as dark boxes, untranslated regions as light boxes.
Vertical lines represent SNPs, with their positions in the sequence indicated.
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AGGT and GCGT), we observe an increase in its frequency
in patients with IBD (0.035, UC and CD combined) as
compared to controls (0.003). This increase in frequency
yields an OR of 13.15 (95%CI 3.17-116.15, P<0.00005,
for UC and CD combined).
In order to test the possibility that these positive
associations are in reality indicative of linkage disequilibrium
with yet undiscovered nearby polymorphisms, we studied
by DHPLC the 19 cases who could carry the risk haplotype.
Regions of PTGS2 surrounding the three SNPs, and in
addition the promoter region, exon 1 and the UTRs were
analyzed. No novel polymorphisms were discovered in the
coding sequence of the gene. One SNP was discovered at
bp 9 850 (A-G), with a minor allele frequency of lower than
2%. Therefore, we considered it unlikely that polymorphisms
other than 5 209 or 8 473 could explain the observed
associations.
DISCUSSION
PTGS2 is a critical enzyme involved in the production of
prostaglandins, which are essential in the process of healing
bowel wounds. The use of NSAIDs, which inhibit both the
translation and activity of PTGS2, can induce a flare-up[21]
and actually exacerbate the symptoms of  IBD[20]. We
hypothesized that polymorphisms in PTGS2 might influence
prostaglandin production in inflamed cells, thus affecting
susceptibility to IBD. In this study, we have found a slightly
increased risk of IBD associated to PTGS2.5209 and
PTGS2.8473, and a strong association with a haplotype
including alleles of these two SNPs.
PTGS2.5209 is in intron 5 of PTGS2. In silico analysis
Table 1  Genotype frequencies and OR for UC and CD of PTGS2 SNPs
Genotype                Controls  UC CD
   n1   %   n1   %            OR (95%CI)2    n1  %            OR (95%CI)2
PTGS2.401
    A/A 277   79 115   82 1.00 107   77 1.00
    A/G   66   19   24   17        0.82 (0.48-1.39)3   30   22        1.17 (0.70-1.94)3
    G/G     7     2     1     1     1     1
    Total 350 100 140 100 138 100
PTGS2.926
    G/G 256   75 112   81 1.00 106   76 1.00
    G/C   75   22   23   17        0.77 (0.47-1.28)3   31   22        1.06 (0.65-1.73)3
    C/C     8     2     4     3     3     2
    Total 339 100 139 100 140 100
PTGS2.3050
    G/G 250   71 109   75 1.00 102   71 1.00
    G/C   99   28   32   22        0.83 (0.52-1.32)3   38   26        0.97 (0.62-1.53)3
    C/C     1     1     4     3     4     3
    Total 350 100 145 100 144 100
PTGS2.5209
    T/T 265   75 110   76 1.00   95   66 1.00
    T/G   81   23   30   21        1.00 (0.62-1.61)3   46   33        1.63 (1.03-2.57)3
    G/G     7     2     5     3     2     1
    Total 353 100 145 100 143 100
PTGS2.8473
    C/C   44   13   18   14 1.003   21   15 1.003
    T/C 147   42   49   34   54   38
    T/T 155   45   78   54        1.50 (1.00-2.27)   68   47        1.10 (0.72-1.68)
    Total 346 100 145 100 143 100
1Numbers may not sum up to the totals of controls or cases due to genotyping failure. All samples that did not give a reliable result in the first round of genotyping were
resubmitted to up to three additional rounds of genotyping. Data points that were still not filled up after this procedure were left blank. 2All ORs are adjusted for sex and
age. 3Heterozygotes and homozygotes for the rare allele have been grouped in order to improve statistical power.
Table 2  PTGS2 haplotype frequencies and OR for IBD
Haplotype1     Controls           UC cases    CD cases                UC+CD cases2
            n (%)             n (%)            OR (95%CI)       n (%)       OR (95%CI)       n (%)      OR (95%CI)3
AGTT        471 (64.7)        193 (65.6)        1.00 (ref.) 183 (62.7)   1.00 (ref.) 376 (64.2) 1.00 (ref.)
AGTC        147 (20.2)          55 (18.7)        0.91 (0.64-1.30)   54 (18.5)   0.95 (0.66-1.35) 109 (18.6) 0.93 (0.69-1.24)
GCGC          64 (8.8)          22 (7.5)        0.84 (0.50-1.39)   27 (9.2)   1.09 (0.67-1.75)   49 (8.4) 0.96 (0.63-1.45)
ACGC          25 (3.4)            8 (2.7)        0.78 (0.35-1.73)     7 (2.4)   0.72 (0.31-1.66)   15 (2.6) 0.75 (0.36-1.51)
AGGT            2 (0.3)          10 (3.4)        12.2 (2.97-inf.)     9 (3.1) 11.58 (2.79-inf.)   19 (3.2) 11.9 (2.83-105.76)
Rare4          19 (2.6)            6 (2.0)        0.77 (0.31-1.90)   12 (4.1)   1.63 (0.78-3.37)   18 (3.1) 1.19 (0.61-2.29)
1The order of SNPs in the haplotypes is PTGS2.401, PTGS2.926, PTGS2.5209, and PTGS2.8473. 2UC and CD combined. 3ORs are not corrected as they are based on
population level haplotype frequencies and are relative to the most common haplotype (AGTT). 4Rare haplotypes (frequency ¡Ü1% in both cases and controls).
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of  this SNP for splice site mutations[31] reveals that the T-G
substitution creates a new splicing acceptor sequence with
nearly the same strength as that found in normal splice
sites. While this is most probably not enough of a change to
exclude completely the normal splicing of  exons 5-6, it could
cause some “leaking”, reducing the amount of  normal
PTGS2 mRNA. PTGS2.8473, being in the 3’ untranslated
region (UTR), could affect the stability of PTGS2 mRNA[33].
In fact, the unusually long 3’ UTR plays an important role
in determining the half-life of  the mRNA. Various proteins
bind to it and cause either acceleration or protection of the
degradation of the mRNA[34,35].
The associations we have found between CD and
PTGS2.5209 G/G, and UC and PTGS2.8473 T/T are
statistically significant, but of moderate importance. We propose
that it is the combination of the G allele at PTGS2.5209
with the T allele at PTGS2.8473, on the same chromosome
(GT haplotype), that would have the most influence on
disease status.
The association between IBD and the GT haplotype could
be due to linkage disequilibrium with another polymorphism
that lies nearby. To test this hypothesis, we have analyzed
subjects who carry the GT haplotype for the presence of
novel functional polymorphisms of PTGS2, but this search
has not yielded any additional candidates. Linkage disequilibrium
with polymorphisms in neighboring genes is not a likely
explanation either, as there is no gene mapping of at less
than 100 kbp on either side of PTGS2.
We are inclined to think that this association is not a
finding by chance. First of all, we have found a higher level
of linkage disequilibrium between alleles at bp 5 209 and
8 473 in controls than in cases. This could mean that natural
selection has exerted pressure toward the disappearance of
the GT haplotype, i.e. this haplotype might negatively affect
the fitness of individuals carrying it. Additionally, we have
observed that this haplotype is virtually absent not only in
the Dutch population, but in other Northern European
populations as well (Cox et al., unpublished data).
These results are the first linking of PTGS2 to IBD.
While the GT haplotype of PTGS2 is rare, the two alleles
that compose it are much more frequent, they both show a
modest association with the disease, and could therefore be
important for a large proportion of the population. Future
steps are to replicate these findings by independent studies,
to determine experimentally the extent to which PTGS2
polymorphisms alter the expression or function of the gene,
and to discover genetic or environmental factors that may
alter the risk of IBD interacting with PTGS2 alleles.
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